Blue Earth Diagnostics   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Oxford United Kingdom (2014)
Status: Acquired by Bracco (2019)

Organization Overview

First Clinical Trial
2015
NCT02578940
First Marketed Drug
2016
Fluciclovine (Axumin)
First NDA Approval
2016
Fluciclovine (Axumin)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BLUE EARTH | Blue Earth Diagnostics | Blue Earth Diagnostics, Inc | Blue Earth Diagnostics Ltd

Active Ingredients

Marketed Drugs (2)

Flotufolastat (Posluma) (2023)

Fluciclovine (Axumin) (2016 NDA)

Drugs in Phase 4 Trials (1)

Fluciclovine (Axumin) (24 trials)

Drugs in Phase 3 Trials (2)

18f-jk-psma-7 (2 trials)

Flotufolastat (Posluma) (3 trials)

Drugs in Phase 2 Trials (3)

abiraterone (zytiga) (1 trial)

furosemide (lasix) (1 trial)

prednisone (meticorten) (1 trial)

Indications

Approved Indications


 

Carcinoma, Ovarian Epithelial

Endometrial Neoplasms

Prostatic Neoplasms

Uterine Cervical Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Brain Neoplasms (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 4)

Carcinoma, Transitional Cell (Phase 1)

Endometrial Neoplasms (Phase 4)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms, Second Primary (Phase 3)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Uterine Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial APIs: 6